India · Delayed Price · Currency is INR Genpharmasec Statistics
Total Valuation
Genpharmasec has a market cap or net worth of INR 692.15 million. The enterprise value is 934.68 million.
| Market Cap | 692.15M |
| Enterprise Value | 934.68M |
Important Dates
The last earnings date was Thursday, May 21, 2026.
| Earnings Date | May 21, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Genpharmasec has 553.72 million shares outstanding. The number of shares has increased by 189.55% in one year.
| Current Share Class | 553.72M |
| Shares Outstanding | 553.72M |
| Shares Change (YoY) | +189.55% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 45.21% |
| Owned by Institutions (%) | n/a |
| Float | 289.94M |
Valuation Ratios
The trailing PE ratio is 47.78.
| PE Ratio | 47.78 |
| Forward PE | n/a |
| PS Ratio | 0.48 |
| PB Ratio | 1.05 |
| P/TBV Ratio | 1.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.34, with an EV/FCF ratio of -5.17.
| EV / Earnings | 58.30 |
| EV / Sales | 0.65 |
| EV / EBITDA | 21.34 |
| EV / EBIT | 42.28 |
| EV / FCF | -5.17 |
Financial Position
The company has a current ratio of 1.71, with a Debt / Equity ratio of 0.53.
| Current Ratio | 1.71 |
| Quick Ratio | 0.84 |
| Debt / Equity | 0.53 |
| Debt / EBITDA | 7.98 |
| Debt / FCF | -1.93 |
| Interest Coverage | 1.78 |
Financial Efficiency
Return on equity (ROE) is 0.86% and return on invested capital (ROIC) is 1.57%.
| Return on Equity (ROE) | 0.86% |
| Return on Assets (ROA) | 1.27% |
| Return on Invested Capital (ROIC) | 1.57% |
| Return on Capital Employed (ROCE) | 2.43% |
| Weighted Average Cost of Capital (WACC) | 3.99% |
| Revenue Per Employee | 143.09M |
| Profits Per Employee | 1.60M |
| Employee Count | 10 |
| Asset Turnover | 1.31 |
| Inventory Turnover | 12.18 |
Taxes
In the past 12 months, Genpharmasec has paid 4.11 million in taxes.
| Income Tax | 4.11M |
| Effective Tax Rate | 42.30% |
Stock Price Statistics
The stock price has decreased by -40.19% in the last 52 weeks. The beta is 0.13, so Genpharmasec's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | -40.19% |
| 50-Day Moving Average | 1.13 |
| 200-Day Moving Average | 1.46 |
| Relative Strength Index (RSI) | 63.31 |
| Average Volume (20 Days) | 360,696 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genpharmasec had revenue of INR 1.43 billion and earned 16.03 million in profits. Earnings per share was 0.03.
| Revenue | 1.43B |
| Gross Profit | 145.15M |
| Operating Income | 22.11M |
| Pretax Income | 9.71M |
| Net Income | 16.03M |
| EBITDA | 43.79M |
| EBIT | 22.11M |
| Earnings Per Share (EPS) | 0.03 |
Balance Sheet
The company has 100.74 million in cash and 349.47 million in debt, with a net cash position of -248.73 million or -0.45 per share.
| Cash & Cash Equivalents | 100.74M |
| Total Debt | 349.47M |
| Net Cash | -248.73M |
| Net Cash Per Share | -0.45 |
| Equity (Book Value) | 656.45M |
| Book Value Per Share | 1.08 |
| Working Capital | 334.96M |
Cash Flow
In the last 12 months, operating cash flow was -175.52 million and capital expenditures -5.21 million, giving a free cash flow of -180.73 million.
| Operating Cash Flow | -175.52M |
| Capital Expenditures | -5.21M |
| Depreciation & Amortization | 21.68M |
| Net Borrowing | 49.69M |
| Free Cash Flow | -180.73M |
| FCF Per Share | -0.33 |
Margins
Gross margin is 10.14%, with operating and profit margins of 1.55% and 1.12%.
| Gross Margin | 10.14% |
| Operating Margin | 1.55% |
| Pretax Margin | 0.68% |
| Profit Margin | 1.12% |
| EBITDA Margin | 3.06% |
| EBIT Margin | 1.55% |
| FCF Margin | n/a |
Dividends & Yields
Genpharmasec does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -189.55% |
| Shareholder Yield | -189.55% |
| Earnings Yield | 2.32% |
| FCF Yield | -26.11% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 11, 2019. It was a forward split with a ratio of 10.
| Last Split Date | Apr 11, 2019 |
| Split Type | Forward |
| Split Ratio | 10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |